Cargando…
Key features of inhibitor binding to the human mitochondrial pyruvate carrier hetero-dimer
OBJECTIVE: The mitochondrial pyruvate carrier (MPC) has emerged as a promising drug target for metabolic disorders, including non-alcoholic steatohepatitis and diabetes, metabolically dependent cancers and neurodegenerative diseases. A range of structurally diverse small molecule inhibitors have bee...
Autores principales: | Tavoulari, Sotiria, Schirris, Tom J.J., Mavridou, Vasiliki, Thangaratnarajah, Chancievan, King, Martin S., Jones, Daniel T.D., Ding, Shujing, Fearnley, Ian M., Kunji, Edmund R.S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968063/ https://www.ncbi.nlm.nih.gov/pubmed/35278701 http://dx.doi.org/10.1016/j.molmet.2022.101469 |
Ejemplares similares
-
The yeast mitochondrial pyruvate carrier is a hetero‐dimer in its functional state
por: Tavoulari, Sotiria, et al.
Publicado: (2019) -
Pathogenic variants of the mitochondrial aspartate/glutamate carrier causing citrin deficiency
por: Tavoulari, Sotiria, et al.
Publicado: (2022) -
The SLC25 Carrier Family: Important Transport Proteins in Mitochondrial Physiology and Pathology
por: Kunji, Edmund R.S., et al.
Publicado: (2020) -
A Single Cysteine Residue in the Translocation Pathway of the Mitosomal ADP/ATP Carrier from Cryptosporidium parvum Confers a Broad Nucleotide Specificity
por: King, Martin S., et al.
Publicado: (2020) -
Substrate binding in the mitochondrial ADP/ATP carrier is a step-wise process guiding the structural changes in the transport cycle
por: Mavridou, Vasiliki, et al.
Publicado: (2022)